Background We wished to determine whether pegylated interferon (PEG-IFN) therapy after curative treatment of hepatocellular carcinoma (HCC) prevents a recurrence of HCC. Methods Thirty-seven HCC patients with hepatitis C virus (HCV) infection who were treated with PEG-IFN after curative treatment (PEG-IFN group) and 145 controls without IFN therapy (non-IFN group) were enrolled. The overall survival and recurrence-free survival rates were compared between the groups, and the predisposing factors for recurrence and survival were analyzed. The rates were also examined by propensity score (PS) matched analysis that could minimize selection biases. Results The median follow-up period was 3.7 years. The 5-year survival rate in the PEG-IFN group (91%) was significantly higher than that in the non-IFN group (56%; P \ 0.01). The rate of the second recurrence but not that of the first recurrence of HCC in the sustained virological responder (SVR) group was lower than that in the non-IFN group (P = 0.03). Improvement of survival by PEG-IFN and low rate of second recurrence in the SVR group were also observed in PS matched analysis. Multivariate analysis revealed that PEG-IFN therapy and high serum albumin were good prognostic factors for survival. Although low serum albumin and large and multiple tumors were risk factors for the first recurrence, non-SVR and low serum albumin were risk factors for the second recurrence. Conclusion PEG-IFN-therapy after curative treatment of HCC improved the rate of survival, and SVR was found to be closely correlated with the prevention of recurrence.
Introduction
Hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide. Chronic infection with hepatitis C virus (HCV) is one of the major causes of HCC [1] [2] [3] , and the percentage of HCC patients with HCV infection is about 70% in Japan. Recent advances in imaging and treatment modalities have improved the prognosis of patients with HCV-related HCC, but outcomes are still unsatisfactory. The 5-year survival rate is only 50-70%, even after curative treatment [4, 5] , such as surgical resection and percutaneous ablation [percutaneous ethanol injection therapy (PEIT), microwave coagulation therapy (MCT), and radiofrequency thermal ablation (RFA)] [6, 7] . This unfavorable prognosis is caused by high intrahepatic tumor recurrence rates and sustained hepatic damage, both correlated with sustained viral infection [8] . The rate of intrahepatic tumor recurrence within 1 year is 20-40%, rising to about 80% by 5 years [9] [10] [11] . Thus, alleviation of the effect of HCV is a high priority for improving the prognosis of patients with HCV-related HCC.
Interferon (IFN) therapy is effective in reducing serum alanine transaminase (ALT) activity and in eradicating HCV [12, 13] . Thus, IFN could have value in minimizing hepatic necrosis, inflammation, and fibrosis, as well as reducing the incidence of HCC. In 1995, a small randomized controlled trial (RCT) showed a reduction in the incidence of HCC in cirrhotic patients with HCV infection by IFN treatment [14] . Yu et al. [15] reported that the cumulative incidences of HCC were 12.2% and 35.2% in IFN-treated and untreated chronic hepatitis C patients, respectively (P = 0.001). Tanaka et al. [16] also reported that interferon therapy decreased the risk of developing HCC by 48% compared with that in a control group (P = 0.064). In addition, several recent studies have shown that IFN therapy, even after curative treatment of HCVrelated HCC, could prevent recurrence and improve the rate of survival [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] . Because these studies used different IFN regimens and the background characteristics of patients were diverse, the results varied, and no standard IFN regimen has been established for patients after curative treatment of HCV-related HCC.
Recently, the administration of pegylated interferon (PEG-IFN) has become the standard treatment for patients with chronic HCV infection. Treatment with PEG-IFN and oral ribavirin produces a virological response in more than 50% of patients, which is better than that in conventional a-IFN therapy [31, 32] . However, there are few reports that demonstrate the effect of PEG-IFN therapy after curative treatment of HCV-related HCC.
The present study involves analysis of the efficacy of PEG-IFN after the curative treatment of HCC for the prevention of HCC recurrence and for improving the rate of survival.
Patients and methods

Patients
From January 1997 until March 2009, 358 consecutive patients with HCV-related HCC underwent curative treatment as an initial treatment at Okayama University Hospital. Here, curative treatment is defined as surgical operation (resection; n = 86), RFA (n = 228), PEIT (n = 30), or MCT (n = 14). Among the patients, 176 patients were excluded because 163 patients had previously received IFN therapy and, for 13 patients, information was lacking on whether they had previously received IFN treatment. The remaining 182 patients were enrolled in the study. Informed consent was obtained from all patients for use of their clinical data. The study protocol conformed to the ethical guidelines of the World Medical Association Declaration of Helsinki, and was approved by the ethical committees of the institute. This study is a retrospective cohort study.
Diagnosis
HCC was diagnosed on the basis of typical findings by ultrasonography, computed tomography (CT) scans, and magnetic resonance imaging (MRI) scans (hyperattenuation in the arterial phase and hypoattenuation in the portalvenous phase). The imaging diagnoses were confirmed by at least two imaging modalities. The diagnosis of HCC was confirmed histopathologically with ultrasound-guided biopsy in nine patients because no typical findings were identified in imaging modalities.
IFN therapy
After curative treatment of primary HCC and confirmed that no residual tumor was existed by imaging modalities, 37 of the 182 patients were assigned to PEG-IFN therapy (PEG-IFN group). The remaining 145 patients did not receive any IFN treatment (non-IFN group). IFN treatment was performed on patients who agreed to use IFN after receiving a full explanation regarding the benefits and side effects of the treatment and who met the following inclusion criteria: (1) tumor-node-metastasis (TNM) stage of I, II, or III; (2) detectable serum HCV-RNA; (3) seronegative for hepatitis B virus surface antigen; (4) Child-Pugh class A or B; (5) platelet count above 80,000/mm 3 ; and (6) age less than 75 years. In the PEG-IFN group, 15 patients received 90-180 lg pegylated interferon alpha-2a (Pegasys; F-Hoffmann-La Roche, Basel, Switzerland) subcutaneously once per week for 24-48 weeks, and 22 patients received 60-100 lg pegylated interferon alpha-2b (PegIntron; Schering-Plough, Kenilworth, NJ, USA) plus ribavirin (Rebetol; Schering-Plough) at 600-800 mg/body for 24-48 weeks, according to the guideline on medical care for chronic hepatitis C prepared by the Ministry of Health, Labor and Welfare of Japan [33] . The median period between the day of curative treatment and PEG-IFN therapy was 242 days.
Patients stopped posttreatment PEG-IFN therapy when HCC recurrence was detected or if the hemoglobin level was \8.5 g/dl, the leukocyte count was \1,000/mm 3 , the neutrophil count was \500/mm 3 , or the platelet count was \50,000/mm 3 , and then restarted the therapy after the treatment of HCC whenever possible.
In the control group (non-IFN group), the patients were prescribed ursodeoxycholic acid (UDCA) and the stronger neo-minophagen C (SNMC).
A sustained virological response (SVR) was defined as HCV-RNA negativity, determined by reverse transcriptionpolymerase chain reaction, more than 6 months after the termination of IFN therapy. The rest of the patients were considered to have exhibited a nonsustained virological response (non-SVR).
Follow-up of the patients
After curative treatment of primary HCC, all patients underwent liver function tests every 1-2 months, and ultrasonography or three-phase dynamic CT scanning every 3 months. The serum levels of alpha-fetoprotein (AFP), AFP-L3, and des-c-carboxy prothrombin (DCP) were also determined every 2-3 months. The recurrence of HCC was diagnosed using the same criteria as for the initial development of HCC.
Statistical analysis
Statistical analysis was performed using SAS version 9.1 package and JMP software, version 8.0 (SAS Institute, Cary, NC, USA). Differences between two groups were evaluated using the unpaired Student's t test. The v 2 test or Fisher's exact probability test was used to compare categorical data. Cumulative incidence curves were determined with the Kaplan-Meier method, and the differences between groups were assessed using the log-rank test. Possible risk factors for survival and HCC recurrence were examined by the Cox proportional hazards regression model with the following 12 variables: interferon-related variables (application of interferon therapy, response to interferon therapy, and HCV genotype), background, liver function, and tumor factors at the first treatment and at recurrence of HCC [age, alanine aminotransferase (ALT), albumin (ALB), total bilirubin (T.Bil), platelet counts (PLT), prothrombin time (PT), AFP, DCP, maximum tumor size, and tumor number]. Parameters that proved to be significant in the univariate analysis were tested by the multivariate Cox proportional hazards regression model.
We also conducted propensity score (PS) matched analysis that can adjust the clinical background of the patients in each group. To calculate PS, we used seven covariates: sex of patients, and variables at the time of development of HCC (age at the time of development of HCC, ALT, ALB, T.Bil, PLT, maximum tumor size, and tumor numbers). The propensity score of choosing the IFN treatment was calculated, followed by matching IFN group and non-IFN group according to a greedy matching technique [34] . The survival and recurrence rates of matched patients were compared by the Kaplan-Meier method and the differences were evaluated by the log-rank test. A P value less than 0.05 was considered statistically significant. Table 1 shows the clinical features of the patients in the PEG-IFN and non-IFN (control) groups at the first treatment of HCC, and Table 2 shows their data at the first recurrence of HCC. Clinical and laboratory characteristics were similar in both groups, but those in the PEG-IFN group were slightly younger (63 vs. 67 years old), and 3 ) than those in the non-IFN group. The median follow-up was 4.6 years for patients receiving PEG-IFN and 3.6 years for the controls. In the PEG-IFN group, 19 patients exhibited an SVR (12 monotherapy and 7 combination therapy), 2 were biochemical responders, and the other 17 patients were nonresponders.
Results
Characteristics of the patients
Adherence and side effects of IFN therapy Life-threatening adverse events were not observed in this study. In 11 cases of mild to moderate toxicity (5 thrombocytopenia, 3 anemia, and 3 neutropenia), IFN dose was reduced by 50%. Three patients eventually discontinued treatment with the drug because of adverse events: depression and severe malaise (n = 1), hemolytic anemia (n = 1), and IFN retinopathy (n = 1). In 8 cases with moderate toxicity, IFN treatment could be continued.
Cumulative survival rates of hepatocellular carcinoma In this study, 2 patients in the PEG-IFN group and 39 patients in the non-IFN group died. All the patients who died had recurrence of HCC. The overall survival rate of PEG-IFN patients was higher than that of non-IFN patients (Fig. 1) . Five-year survival rates of the PEG-IFN and non-IFN groups were 91% and 65%, respectively (P \ 0.01).
Recurrence of hepatocellular carcinoma
At the end of the study, recurrence of HCC had occurred in 8 patients (42%) in the SVR group, 10 (55%) in the non-SVR group, and 63 (43%) in the non-IFN group.
The rate of first HCC recurrence after curative therapy of HCC in SVR patients tended to be lower than that in non-IFN patients (48 vs. 70% at 5 years, respectively, P = 0.05; Fig. 2) ; however, there was no significant difference between non-SVR patients and non-IFN patients (72 vs. 70% at 5 years, respectively; P = 0.73). In addition, there was no significant difference between the PEG-IFN group and the non-IFN group (58 vs. 70% at 5 years, respectively; P = 0.17). At first HCC recurrence, there was no significant difference in tumor number or liver function between the PEG-IFN and non-IFN groups; however, maximum tumor size in the PEG-IFN group was smaller than that in the non-IFN group (13 vs. 16 mm, respectively; P = 0.03). Fifteen of the 17 patients in the PEG-IFN group underwent curative treatment at the first recurrence of HCC.
The rate of second recurrence was not significantly different between the PEG-IFN and non-IFN groups (78 vs. 83% at 3 years, respectively; P = 0.26). However, the rate in the SVR group was significantly lower than that in the non-IFN group (65 vs. 83% at 3 years, respectively, P = 0.03; Fig. 3 ). At second HCC recurrence, in the PEG-IFN group, maximum tumor size was smaller (12 vs. All variables are shown as the median (range) unless otherwise noted IFN interferon, PEG-IFN pegylated interferon, HCV hepatitis C virus, RFA radiofrequency thermal ablation, ope operation, PEIT percutaneous ethanol injection therapy, MCT microwave coagulation therapy, SVR sustained virological response, ALB albumin, T.Bil total bilirubin, ALT alanine aminotransferase, PLT platelet, PT prothrombin time, AFP alpha-fetoprotein, DCP des-c-carboxy prothrombin 15 mm, respectively; P = 0.02) and serum ALB was higher (3.3 vs. 3.1 g/dl, respectively; P = 0.04) than that in the non-IFN group.
Propensity score matched analysis
To minimize the biases of the PEG-IFN group and non-IFN group, we conducted a propensity score (PS) matched analysis. Thirty-four matched pairs were selected from the PEG-IFN group and non-IFN group by PS. No significant difference in clinical characteristics was observed between the groups (Table 3) . Eighteen patients exhibited an SVR [11 monotherapy and 7 combination therapy, 9 (43%) genotype 1b high and 9 (69%) others]. Overall survival rate of the PEG-IFN group was higher than that of the non-IFN group (P = 0.04; Fig. 4 ). Although no significant difference in the first and second HCC recurrence (P = 0.55 and 0.62, respectively) was observed between the IFN group and non-IFN group, the rate of second recurrence in the SVR group was significantly lower than that in the non-IFN group (65 vs. 79% at 3 years, respectively, P = 0.01; Figs. 5, 6).
Prognostic factors and risk factors of HCC recurrence
To identify the factors that contributed to survival and the recurrence of HCC, a Cox proportional hazard analysis was performed. Univariate analysis showed that PEG-IFN therapy, low T.Bil, and high serum ALB were independent factors favorably associated with long survival. Among the factors that were significant in the analysis, PEG-IFN therapy [risk ratio = 2.72; 95% confidence interval (CI), 1.29-9.04] and a serum ALB level [3.5 g/dl (risk ratio = 2.51; 95% CI, 1.29-4.98) were shown to be significantly associated with better survival in the multivariate analysis (Table 4) .
On the other hand, non-SVR, low ALB, and large and multiple tumors at the initial treatment were significantly Fig. 1 Cumulative survival rates of pegylated interferon (PEG-IFN) group and noninterferon (non-IFN) group. Two patients in the PEG-IFN group died during the observation period. The survival rate was significantly different between the three groups (P = 0.01). SVR sustained virological response Fig. 2 The rates of first hepatocellular carcinoma (HCC) recurrence. The recurrence rate in SVR patients tended to be lower than that in non-IFN patients (48 vs. 70% at 5 years, respectively; P = 0.05); however, there was no significant difference between non-SVR patients and non-IFN patients (72 vs. 70% at 5 years, respectively; P = 0.73). SVR sustained virological response associated with first recurrence of HCC in univariate analysis. Multivariate analysis showed that low ALB (risk ratio = 1.70; 95% CI, 1.11-2.56) and large (risk ratio = 1.65; 95% CI, 1.02-2.59) and multiple (risk ratio = 1.66; 95% CI, 1.05-2.56) tumors were independent risk factors; however, response to PEG-IFN therapy was not determined to be a significant factor for the first recurrence of HCC (risk ratio = 1.60; 95% CI, 0.83-3.48; Table 5 ).
Regarding the second recurrence of HCC, non-SVR (risk ratio = 2.51; 95% CI, 1.06-7.40) and low ALB at the first recurrence of HCC (risk ratio = 2.56; 95% CI, 1.46-4.83) were found to be independent risk factors in multivariate analysis as well as univariate analysis (Table 6 ).
Discussion
Persistent active hepatitis is common in the advanced stage of chronic HCV infection and is a risk factor for the development of HCC. Several reports have shown the inhibitory effects of IFN therapy on the development of HCC. In these reports, the inhibitory effect was considered to be the result of the remission of inflammation, necrosis, and fibrosis in addition to the direct action of IFN on tumor cells [35] [36] [37] [38] [39] . Recently, several studies were conducted to show the effect of IFN therapy after curative treatment of HCC, which reduced the risk for recurrence and improved the rate of survival. To date, reports on eight randomized control trials (RCTs) [17] [18] [19] [20] [21] [22] [23] [24] and six non-RCTs [25] [26] [27] [28] [29] [30] on this effect have been published. Fig. 3 Rates of second HCC recurrence. The second recurrence rate in the SVR group was significantly lower than that in the non-IFN group (65 vs. 83% at 3 years, respectively; P = 0.03. SVR sustained virological response Fig. 4 Cumulative survival rates of PEG-IFN group and non-IFN group after propensity score (PS) matching. Overallsurvival rate of the PEG-IFN group was higher than that of non-IFN group (P = 0.04). SVR sustained virological response Fig. 5 Rates of first HCC recurrence after PS matching. We found no significant differences between the two groups with respect to first HCC recurrence (P = 0.55). SVR sustained virological response Fig. 6 Rates of second HCC recurrence after PS matching. The second recurrence rate in the SVR group was significantly lower than that in the non-IFN group (65 vs. 79% at 3 years, respectively; P = 0.01), although no statistical difference was observed between the IFN group and non-IFN group (P = 0.62). SVR sustained virological response However, there have been few trials involving PEG-IFN therapy.
In this study, the overall survival rate of PEG-IFNtreated patients was higher than that of non-IFN patients, and the HCC recurrence rate after curative therapy for HCC in SVR patients was significantly lower than that in non-IFN patients. The survival rates are not different, although the rates of first and second recurrence of the PEG-IFN group (SVR) and PEG-IFN group (non-SVR) were different. The main reason for this discrepancy is that [17] . We conducted propensity score (PS) matched analysis to adjust the clinical background of the patients in each group. PS in this analysis is a probability of choosing PEG-IFN treatment among the patients that was calculated using seven covariates. By matching the score of the patients in the PEG-IFN group and non-IFN group, we could reconstruct a situation similar to randomization.
PEG-IFN is considered to be more beneficial than non-PEG because it results in the SVR rate being higher and the IFN concentration being maintained at a high level for a longer period [40, 41] , which is favorable for its action as a direct anticancer agent. However, there was no difference between conventional IFN and PEG-IFN with regard to the prevention of only late (second) recurrence. We did not compare the effect of PEG-IFN with that of non-PEG-IFN directly, but our results that non-SVR was an independent risk factor for second recurrence but not for first recurrence suggested that IFN treatment after curative treatment of HCC is more beneficial for the suppression of de novo HCC than for preventing the progression of preexisting very small HCC or intrahepatic metastasis, regardless of the type of interferon used.
In the PEG-IFN group, tumor size at HCC recurrence was smaller (13 vs. 16 mm, respectively; P = 0.03) and liver function tended to be better (T.Bil, ALB, PLT, PT) than in the non-IFN group. These results suggested that PEG-IFN might inhibit the growth of recurrent tumors as well as preserve liver function, although the inhibitory effect does not appear to be sufficient for complete prevention of recurrence.
PEG-IFN therapy after curative treatment of HCC was generally well tolerated in our study. Among the 37 patients, the PEG-IFN dose had to be reduced for 8 patients (21%); however, only 3 (8%) discontinued treatment with the drug because of adverse events. This rate was similar to that of the non-PEG-IFN group after HCC treatment (8-15%) [17] [18] [19] [20] [21] [22] [23] [24] . However, PEG-IFN therapy has fewer side effects than non-PEG-IFN therapy, such as high-grade fever and general fatigue. The good adherence of patients to treatment should be noted, with a low rate of withdrawal as a consequence of adverse events [32] . The number of elderly patients with HCC will increase in the future. Because of fewer side effects and a higher rate of SVR, HCV-related HCC treatment with PEG-IFN should be considered for these elderly patients.
The weak point of this study is that it is a retrospective study and it is difficult to eliminate biases completely even with PS analysis, although no statistical difference was observed between the PEG-IFN group and non-IFN group. RR risk ratio, CI confidence interval, IFN interferon, PEG-IFN pegylated interferon, HCV hepatitis C virus, HCC hepatocellular carcinoma, SVR sustained virological response, ALB albumin, T.Bil total bilirubin, ALT alanine aminotransferase, PLT platelet, PT prothrombin time, AFP alpha-fetoprotein, DCP des-c-carboxy prothrombin * P values less than 0.05 were considered statistically significant
In conclusion, the present study suggests that PEG-IFN therapy after curative treatment of HCC can improve the prognosis and inhibit the recurrence of HCV-related HCC. This work involved a nonrandomized study, so further prospective studies with a larger number of cases are required to reach firm conclusions.
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